2026 Medical Fee Schedule Revision: What’s the Impact on Practicing Physicians? – Nikkei Medical

2026 Medical Fee Schedule Revision and Medical M&A / Business Succession

The article reported by Nikkei Medical regarding the 2026 medical fee schedule revision serves as a reminder to medical institution managers of the importance of management decisions in response to changes in revenue structure. Specifically, the concrete directions of the revision, such as the stricter facility standards and the expanded utilization of regional medical collaboration promotion corporations, suggest the difficulty for individual medical institutions to cope independently.

Such regulatory trends are extremely important in the context of medical M&A and business succession. As a medium-to-long-term management strategy anticipating the revision cycle, mergers and group formations that pursue economies of scale can be effective options for maintaining facility standards, distributing the burden of capital investment, and securing specialized personnel. Particularly, to address facility standards that may become difficult to maintain independently, resource sharing and enhanced collaboration within a group will be key to business continuity.

For medical institution managers facing succession issues, or readers considering future management strategies, it is crucial to view the current trends in medical fee schedule revisions not merely as regulatory changes, but as an opportunity to concretely consider business succession and M&A strategies. To ensure adaptability to regulatory changes and sustainable revenue, we recommend consulting with experts early to explore the optimal options tailored to your institution's management situation.